Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
Date: September 16, 2023
National Stock Exchange of India Ltd. (Scrip Code:
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - information on reported
This is in reference to Regulation 30(11) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") regarding a news item published
in The Economic Times (newspaper/ media) on September 16, 2023, with the heading "Dr Reddy's Laboratories jumps into the fray for
Biogen's biosimilars".
The said news item is about "Dr Reddy's Laboratories
(DRL) is reportedly in the race to acquire the biosimilar products portfolio of Biogen, a US-based biotech company". In this regard,
please note that the Company does not comment on market speculations and there is currently no such information which requires disclosure
under Regulation 30 of the SEBI Listing Regulations.
In compliance with Regulation 30 of the SEBI Listing
Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure
under the said Regulations.
This is for your information.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer and Head-CSR